[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-pregnancy-induced\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-pregnancy-induced":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,79,111,137,169,203,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100502797","optimizing-cardiovascular-preventive-care-for-women-following-hypertensive-disorders-of-pregnancy-100502797",false,"NCT05826925","Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy","Inclusion Criteria:\n\n* Delivered a pregnancy complicated by a hypertensive disorder of pregnancy at the University of Utah during the current hospital admission\n* Ability to speak and read English or Spanish\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Cardiovascular disease diagnosis (history of peripheral artery disease, stroke, or myocardial infarction)\n* Impairment of cognitive function or vision that prohibits communication and\u002For reading the decision aid.",true,"FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cardiovascular disease is the leading cause of death among women in the United States, and women with hypertensive disorders of pregnancy have a 2-fold higher risk for cardiovascular disease later in life compared to women with uncomplicated pregnancies. This research investigates a patient-centered intervention during the postpartum period to promote engagement in cardiovascular preventive care.",[26,27,28,29,30],"Hypertension, Pregnancy Induced","Hypertension Complicating Pregnancy","Preeclampsia","Cardiovascular Diseases","Patient Engagement","RECRUITING","2026-06-22",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":20},"2026-07-15",{"date":39,"type":20},"2027-08",{"name":41,"class":42},"University of Utah","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":43},"100641377","polyphenol-intake-mediterranean-diet-adherence-and-oxidative-stress-in-pregnancy-100641377","NCT07656532","Polyphenol Intake, Mediterranean Diet Adherence, and Oxidative Stress in Pregnancy","Effect of Polyphenol Intake and Adherence to the Mediterranean Diet on Oxidative Stress During Pregnancy","PREGPOLY","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older.\n* Singleton pregnancy.\n* Gestational age between 8 and 11 weeks at enrollment.\n* Receiving prenatal care within the Salamanca Health Area.\n* Able to understand the study information and provide written informed consent.\n* No clinical restrictions that would contraindicate dietary modifications.\n\nExclusion Criteria:\n\n* Medical or obstetric conditions that contraindicate dietary modifications.\n* Active metabolic, renal, or hepatic disease.\n* Severe hyperemesis gravidarum or gastrointestinal disorders limiting food intake.\n* Allergy or intolerance to cocoa.\n* Habitual high cocoa or chocolate consumption (\\>30 g\u002Fday).\n* Multiple pregnancy.\n* Severe obstetric complications diagnosed before enrollment.\n* Inability to comply with study procedures, attend follow-up visits, or communication barriers that could interfere with participation.",{"count":53,"type":20},60,[23],"This study is a randomized controlled clinical trial designed to evaluate the effect of a polyphenol-rich dietary intervention during pregnancy on endothelial function, oxidative stress biomarkers, and maternal and neonatal outcomes.\n\nPregnancy is associated with metabolic and vascular adaptations, and complications such as gestational diabetes and hypertensive disorders are linked to endothelial dysfunction and increased oxidative stress. Dietary factors, particularly adherence to the Mediterranean diet and intake of polyphenol-rich foods, may play a protective role.\n\nPregnant women will be randomly assigned to either an intervention group or a control group. The intervention consists of daily consumption of 10 g of natural non-alkalized cocoa and structured dietary counseling aimed at achieving at least five daily servings of fruits and vegetables, alongside general Mediterranean diet recommendations.\n\nThe intervention will last 12 weeks, from early to mid-pregnancy. Biomarkers of endothelial function and oxidative stress will be measured at different time points, along with clinical maternal outcomes (including gestational diabetes and hypertensive disorders) and neonatal outcomes.\n\nThe aim is to determine whether this dietary intervention improves endothelial function, reduces oxidative stress, and contributes to better pregnancy outcomes.",[57,58,28,59,60,61],"Pregnancy","Gestational Diabetes Mellitus (GDM)","Hypertension, Pregnancy-Induced","Oxidative Stress","Endothelial Dysfunction",[63,64,65,66,67,68],"Mediterranean diet","Polyphenols","Cocoa supplementation","Oxidative stress","Endothelial function","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-14",{"date":72,"type":35},"2026-06-18",{"date":74,"type":20},"2026-09-01",{"date":76,"type":20},"2028-10-01",{"name":78,"class":42},"University of Salamanca",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":90,"conditions":91,"keywords":101,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":43},"100537733","phase-4-treatment-with-aspirin-after-preeclampsia-tap-trial-100537733","NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","55 Years",{"count":53,"type":20},[89],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[92,93,94,95,96,29,97,98,99,26,100],"Hypertensive Disorder of Pregnancy","Pre-Eclampsia","Hypertension","Eclampsia","Gestational Hypertension","Toxemia","Pregnancy Complications","Vascular Diseases","Hypertension;Pre-Eclamptic",[94],"2026-06-03",{"date":104,"type":35},"2026-06-04",{"date":106,"type":35},"2024-05-29",{"date":108,"type":20},"2027-09-01",{"name":110,"class":42},"Malamo Countouris",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100609030","randomized-controlled-trial-of-two-mobile-health-strategies-to-manage-postpartum-hypertension-100609030","NCT07209254","Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension","SMART BP","Inclusion Criteria:\n\n* Age ≥18 years\n* Delivery within 14 days\n* Diagnosis of preeclampsia or gestational hypertension with or without severe features during pregnancy or within 14 days postpartum\n* Initiation of blood pressure medication prior to hospital discharge and up to 14 days postpartum\n* English or Spanish speaking (able to read\u002Funderstand consent and instructions)\n* Has phone texting capabilities\n\nExclusion Criteria:\n\n* Diagnosis of chronic hypertension prior to delivery (would therefore include super imposed preeclampsia)\n* Pre-existing cardiovascular disease (including prior myocardial infarction, stroke, heart failure with reduced ejection fraction, ventricular tachycardia, prior cardiac arrest, pacemaker, severe valvular heart disease, or prior cardiac surgery)\n* Chronic kidney disease (stage 3 or higher)\n* Using ≥3 BP medications at time of enrollment",{"count":119,"type":20},770,[23],"A multicenter randomized trial that will compare the effectiveness of two postpartum blood pressure (BP) management strategies in improving blood pressure and cardiac function and increasing patient engagement and feeling of control over one's health",[26],[124,125,28,126],"Postpartum Hypertension","Blood pressure management","Hypertension, pregnancy induced","2026-05-20",{"date":129,"type":35},"2026-05-22",{"date":131,"type":35},"2026-03-02",{"date":133,"type":20},"2029-11",{"name":135,"class":42},"Jennifer Lewey, MD, MPH",3,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":145,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100638145","community-support-and-mobile-apps-to-help-black-women-control-high-blood-pressure-after-pregnancy-100638145","NCT07606027","Community Support and Mobile Apps to Help Black Women Control High Blood Pressure After Pregnancy","Postpartum Remote Monitoring and Integration of Mobile Health With Engagement From Community Health Workers for Regulating Elevated Blood Pressure","PRIME CARE","Inclusion Criteria:\n\n* Black\u002F African American patients\n* Age: 19 and 50 years of age\n* Diagnosis: Hypertension Disorders of Pregnancy\n* Enrolled in STAMPP-HTN for first 6 weeks postpartum\n\nExclusion Criteria:\n\n* Age: \\\u003C19 years\n* Significant Kidney or Liver disease that may limit antihypertensive medication adjustment","19 Years","50 Years",{"count":148,"type":20},404,[23],"The goal of this randomized clinical trial is to evaluate the effectiveness of a collaborative care intervention, consisting of remote blood pressure monitoring and support from community health workers, in improving blood pressure control and reducing postpartum complications among Black women with hypertensive disorders of pregnancy (HDP). The primary objectives are to determine whether the intervention leads to improved blood pressure control at 12 months postpartum compared to standard care, and whether it reduces the incidence of serious maternal morbidity, including hospitalizations and cardiovascular events. Secondary objectives include examining whether patient activation and trust in the healthcare system mediate the relationship between the intervention and clinical outcomes. Participants will be enrolled at approximately 6 weeks postpartum and randomized to either the collaborative care intervention or standard postpartum care. All participants will self-monitor blood pressure using a provided device, receive guidance on hypertension management, and complete study assessments at multiple time points. Participants assigned to the intervention arm will additionally receive ongoing support from community health workers, including health education, care coordination, and assistance with healthcare navigation. Clinical outcomes and patient-reported measures will be assessed over a 12-month follow-up period.",[152,26,153,124],"Hypertensive Disorders of Pregnancy (HDP)","Severe Maternal Morbidity",[59,155,156,157,158,159],"Postpartum Period","Remote Blood Pressure Monitoring","Community Health Workers","Postpartum Care","African American Women","2026-05-19",{"date":162,"type":35},"2026-05-26",{"date":164,"type":20},"2026-07-01",{"date":166,"type":20},"2031-06-30",{"name":168,"class":42},"University of Nebraska",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":43},"100620750","phase-4-lda-and-lmwh-vs-lda-alone-in-high-risk-patients-for-preeclampsia-prevention-100620750","NCT07361679","LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","Combined Administration of Low Molecular Weight Heparin and Aspirin Versus Aspirin Alone in Gravidas at High Risk for Preeclampsia: A Randomized Controlled Trial","preGO","Inclusion Criteria:\n\n* Singleton pregnancy\n* High risk for preeclampsia (risk \\>1:150) based on FMF screening algorithm combining first-trimester ultrasound, biochemical markers, and medical history\n* Gestational age \\\u003C16 weeks at enrollment\n* Maternal age ≥18 years\n* Willing and able to provide written informed consent\n* Adequate ability for follow-up (direct telephone communication, accessible residence)\n\nExclusion Criteria:\n\n* Multiple pregnancy\n* Current permanent aspirin use for other medical indications\n* Serious congenital fetal abnormality detected on ultrasound\n* Contraindication to aspirin or low molecular weight heparin including: known hypersensitivity, active peptic ulcer disease, bleeding disorders or coagulopathy, severe thrombocytopenia (platelet count \\\u003C100,000\u002FμL), active or recent significant bleeding, history of heparin-induced thrombocytopenia\n* Pre-existing severe renal failure (creatinine clearance \\\u003C30 mL\u002Fmin)\n* Unable to provide informed consent\n* Low probability of adequate follow-up (residence in remote areas without telephone access, accommodation in temporary structures)",{"count":178,"type":20},100,[89],"Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.",[182,183,28,98,59,96],"Preeclampsia Severe","Toxemia Of Pregnancy",[185,186,187,188,189,190,191,192,193],"preeclampsia","gestational hypertension","toxemia","Preeclampsia prevention","Low molecular weight heparin","tinzaparin","High-risk pregnancy","LMWH","Maternal-fetal medicine","2026-01-15",{"date":196,"type":35},"2026-01-23",{"date":198,"type":35},"2023-01-18",{"date":200,"type":20},"2027-07-01",{"name":202,"class":42},"Alexandra Hospital, Athens, Greece",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":224},"100533046","reducing-the-risk-of-chronic-hypertension-and-improving-vascular-function-following-preeclampsia-100533046","NCT06220721","Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia","REPAIR","Inclusion Criteria:\n\n* Hypertensive disorders of pregnancy (HDP) diagnosis, specifically gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines\n* Postpartum day 0-4\n* Age ≥ 18 years\n* Able to communicate in English or in Spanish\n* Has an established OBGYN at an MCW or NU health system practice that has access to Epic electronic medical records.\n\nExclusion Criteria:\n\n* Pre-gestational hypertension\n* Type 1 or type 2 diabetes mellitus\n* Admitted to intensive care unit at the time of screening\n* Diagnosed with HDP during postpartum readmission after discharge from delivery hospitalization\n* Getting discharged on the day of screening\n* Known allergy or contraindication to nifedipine ER\n* Inability or unwillingness to provide informed consent\n* Already taking long-acting antihypertensive medication for standard care\n* Maternal conditions that impact study outcomes: sickle cell disease, systemic lupus erythematosus",{"count":211,"type":20},618,[23],"The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.",[59],"2025-05-07",{"date":217,"type":35},"2025-05-11",{"date":219,"type":35},"2024-10-23",{"date":221,"type":20},"2029-06-30",{"name":223,"class":42},"Medical College of Wisconsin",2,{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":21,"phases":236,"briefSummary":238,"conditions":239,"keywords":241,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":43},"100474631","phase-3-treatment-preventive-for-pre-eclampsia-by-acetylsalicylic-acid-in-women-who-underwent-frozen-embryo-transfer-100474631","NCT05460416","Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer","A Prospective Interventional Randomized Controlled Trial to Assess the Effect of Low Dose Acetylsalicylic Acid As a Preventive Treatment of Pre-eclampsia in Pregnant Women Who Underwent Frozen Embryo Transfer","TePPAFET","Inclusion Criteria:\n\n* Healthy women from \\[18 - 43\\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle\n* Who have given their informed consent\n* Who have a confirmed pregnancy at week 6 of amenorrhea.\n\nExclusion Criteria:\n\n* Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \\> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\\>140\u002F90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \\>126mg\u002Fdl)\n* Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose)\n* Already treated with acetylsalicylic acid\n* Treatment with anticoagulants or non-steroid anti-inflammatory drugs","43 Years",{"count":235,"type":20},276,[237],"PHASE3","Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer",[240,26],"Embryo Transfer",[242,243],"embryo transfer","Hypertension, Pregnancy induced","2025-02-14",{"date":246,"type":35},"2025-02-18",{"date":248,"type":35},"2022-10-25",{"date":250,"type":20},"2026-06-30",{"name":252,"class":42},"Centre Hospitalier Universitaire de Liege"]